AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25861013 — intervention group
Group type: COMPARATOR
Intervention: EE
Number of subjects: 27
Study 23616308 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased self-efficacy
Number of subjects: 0
Study 23616308 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased self-efficacy
Number of subjects: 0
Study 21461325 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue Stabilizing Device (TSD)
Number of subjects: 39
Study 21461325 — intervention group
Group type: COMPARATOR
Intervention: Mandibular Advancement Splint (MAS)
Number of subjects: 39
Study 18430965 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 300 mg weekly for 16 weeks
Number of subjects: 61
Study 18430965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 17634176 — intervention group
Group type: EXPERIMENTAL
Intervention: High phytate diet
Number of subjects: 29
Study 17634176 — intervention group
Group type: COMPARATOR
Intervention: Low phytate diet
Number of subjects: 29
Study 12946082 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-assisted cognitive behaviour therapy (MACT)
Number of subjects: 480
Study 12946082 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 480
Study 12946082 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measures
Number of subjects: 480
Study 11121913 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole, tinidazole, and clarithromycin for 10 days (group OTC)
Number of subjects: 109
Study 11121913 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy based on the susceptibility test (group SUSC)
Number of subjects: 109
Study 9545884 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-containing fissure sealant (Helioseal-F)
Number of subjects: 204
Study 9545884 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fissure sealants)
Number of subjects: 204
Study 8362175 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 14
Study 8362175 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 14
Study 3519237 — intervention group
Group type: EXPERIMENTAL
Intervention: oxprenolol + placebo
Number of subjects: 10
Study 3519237 — intervention group
Group type: EXPERIMENTAL
Intervention: oxprenolol + sulphinpyrazone
Number of subjects: 10
Study 3519237 — intervention group
Group type: COMPARATOR
Intervention: oxprenolol
Number of subjects: 10
Study 29534507 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO mouth rinse
Number of subjects: 9
Study 29534507 — intervention group
Group type: COMPARATOR
Intervention: PLA mouth rinse
Number of subjects: 9
Study 28929932 — intervention group
Group type: EXPERIMENTAL
Intervention: Care costs for patients with hip fractures
Number of subjects: 0
Study 28929932 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-fracture functional status
Number of subjects: 0
Study 28929932 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital costs
Number of subjects: 0
Study 28929932 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive programmes and comprehensive geriatric care
Number of subjects: 0
Study 24922162 — intervention group
Group type: EXPERIMENTAL
Intervention: It's Your Game . . . Keep It Real (IYG)
Number of subjects: 766
Study 24922162 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 766
Study 22415409 — intervention group
Group type: EXPERIMENTAL
Intervention: VeinViewer®
Number of subjects: 111
Study 22415409 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 111
Study 20647107 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibringe
Number of subjects: 0
Study 20647107 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation
Number of subjects: 0
Study 20647107 — intervention group
Group type: COMPARATOR
Intervention: Syringe irrigation
Number of subjects: 0
Study 18562773 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) supplementation (1 g/kg body weight)
Number of subjects: 19
Study 18562773 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 19
Study 15799734 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% gel topically
Number of subjects: 54
Study 15799734 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% solution subconjunctivally
Number of subjects: 54
Study 12057986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 1117
Study 12057986 — intervention group
Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 1117
Study 10696399 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated chaddars and top-sheets
Number of subjects: 395
Study 10696399 — intervention group
Group type: COMPARATOR
Intervention: Placebo-treated chaddars
Number of subjects: 395
Study 8712196 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial targeted intervention (TI)
Number of subjects: 301
Study 8712196 — intervention group
Group type: COMPARATOR
Intervention: Social visit (SV)
Number of subjects: 301
Study 1897347 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine 4 ml.h‐1 (BUPI‐group)
Number of subjects: 60
Study 1897347 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg morphine bolus followed by 0.2 mg.h‐1 (MO‐group)
Number of subjects: 60
Study 1897347 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bupivacaine and morphine (COMB-group)
Number of subjects: 60
Study 6856079 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol (Omnipaque)
Number of subjects: 0
Study 6856079 — intervention group
Group type: COMPARATOR
Intervention: Meglumine‐Ca‐metrizoate (Isopaque cerebral)
Number of subjects: 0
Study 30239650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenicriviroc (dual CCR5/CCR2 antagonist)
Number of subjects: 2
Study 30239650 — intervention group
Group type: EXPERIMENTAL
Intervention: CCR5 delta-32 allele
Number of subjects: 2
Study 30239650 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 2
Study 30239650 — intervention group
Group type: COMPARATOR
Intervention: Cenicriviroc (100 mg dose)
Number of subjects: 2
Study 28144810 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention group (skill building training program)
Number of subjects: 304
Study 28144810 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 304
Study 26491109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (pooled doses)
Number of subjects: 0
Study 26491109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 26491109 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor vs. placebo
Number of subjects: 0
Study 23030511 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulsed Nd:YAG laser (LPNY) treatment
Number of subjects: 27
Study 23030511 — intervention group
Group type: COMPARATOR
Intervention: Control site (untreated side)
Number of subjects: 27
Study 22264573 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily
Number of subjects: 36
Study 22264573 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 80 mg daily
Number of subjects: 36
Study 22264573 — intervention group
Group type: EXPERIMENTAL
Intervention: Both statins
Number of subjects: 36
Study 20528598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate alone
Number of subjects: 0
Study 20528598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate and montelukast
Number of subjects: 0
Study 20528598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17089419 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher weekly contact hours
Number of subjects: 112
Study 17089419 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient ratings of expressed emotion (EE)
Number of subjects: 112
Study 17089419 — intervention group
Group type: EXPERIMENTAL
Intervention: General Health Questionnaire
Number of subjects: 112
Study 17089419 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of Caregiving Inventory
Number of subjects: 112
Study 17089419 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐report Family Inventory
Number of subjects: 112
Study 17089419 — intervention group
Group type: EXPERIMENTAL
Intervention: Inventory of Interpersonal Problems
Number of subjects: 112
Study 16298490 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat-increasing information
Number of subjects: 100
Study 16298490 — intervention group
Group type: COMPARATOR
Intervention: No-threat condition (reassuring information)
Number of subjects: 100
Study 16298490 — intervention group
Group type: EXPERIMENTAL
Intervention: Focusing on sensory pain sensations
Number of subjects: 100
Study 16298490 — intervention group
Group type: EXPERIMENTAL
Intervention: Focusing on affective components of pain
Number of subjects: 100
Study 11978646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle exercise (approximately 70% peak oxygen consumption)
Number of subjects: 13
Study 11978646 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 13
Study 11978646 — intervention group
Group type: COMPARATOR
Intervention: Hyperinsulinemic-euglycemic clamps
Number of subjects: 13
Study 10404908 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir (10 mg once daily for 4 weeks)
Number of subjects: 1107
Study 10404908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1107
Study 7758492 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 4.5 mg/kg once daily
Number of subjects: 100
Study 7758492 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin 1.5 mg/kg every eight hours (thrice daily)
Number of subjects: 100
Study 1691243 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT) at lower doses (500-600 mg/day)
Number of subjects: 0
Study 1691243 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies targeting different viral replicative sites
Number of subjects: 0
Study 623512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine hydrochloride (Flexeril)
Number of subjects: 0
Study 623512 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (Valium)
Number of subjects: 0
Study 623512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30420161 — intervention group
Group type: EXPERIMENTAL
Intervention: benznidazole
Number of subjects: 1508
Study 30420161 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1508
Study 28797349 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-based prediction model (ABC-CHD model) including NT-proBNP, hs-cTnT, low-density lipoprotein cholesterol, age, smoking, diabetes mellitus, and peripheral arterial disease
Number of subjects: 13164
Study 28797349 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 13164
Study 28797349 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 13164
Study 28797349 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol
Number of subjects: 13164
Study 28797349 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 13164
Study 25497439 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (200mg/d)
Number of subjects: 24
Study 25497439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24119112 — intervention group
Group type: EXPERIMENTAL
Intervention: TY 8 mg (bisoprolol transdermal patch)
Number of subjects: 0
Study 24119112 — intervention group
Group type: EXPERIMENTAL
Intervention: BO 5 mg (bisoprolol fumarate oral formulation)
Number of subjects: 0
Study 24119112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24119112 — intervention group
Group type: EXPERIMENTAL
Intervention: TY 8 mg
Number of subjects: 0
Study 21801451 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement strategy training combined with falls prevention education
Number of subjects: 0
Study 21801451 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance strength training combined with falls prevention education
Number of subjects: 0
Study 21801451 — intervention group
Group type: COMPARATOR
Intervention: Generic life-skills social program
Number of subjects: 0
Study 19497571 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (listening to favorite music for 30 min)
Number of subjects: 60
Study 19497571 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (listening to a blank disc for 30 min)
Number of subjects: 60
Study 19497571 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 60
Study 16677243 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (50 microg bid)
Number of subjects: 11
Study 16677243 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (25 microg bid)
Number of subjects: 11
Study 16677243 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Fluticasone and Salmeterol
Number of subjects: 11
Study 16677243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 15262663 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline, 200 mg daily for 12 months
Number of subjects: 491
Study 15262663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 491
Study 15262663 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 491
Study 12359793 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg/d for 2 days, then 0.25 mg/kg/d for 2 days)
Number of subjects: 30
Study 12359793 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 12359793 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 30
Study 9695133 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupron injections (GnRH agonist) followed by transdermal estradiol (Patch)
Number of subjects: 24
Study 9695133 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupron injections (GnRH agonist) followed by resuming menstrual cycles (Cycle)
Number of subjects: 24
Study 9695133 — intervention group
Group type: COMPARATOR
Intervention: Control group (Lupron injections only)
Number of subjects: 24
Study 8567778 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 120 mg/day
Number of subjects: 77
Study 8567778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 2475059 — intervention group
Group type: EXPERIMENTAL
Intervention: lactose-free soy formula
Number of subjects: 100
Study 2475059 — intervention group
Group type: EXPERIMENTAL
Intervention: low-lactose low-fat cow's milk formula
Number of subjects: 100
Study 2475059 — intervention group
Group type: COMPARATOR
Intervention: four different oral refeeding regimes
Number of subjects: 100
Study 873718 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 8‐1998
Number of subjects: 30
Study 873718 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 30
Study 29221475 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 16
Study 26219426 — intervention group
Group type: EXPERIMENTAL
Intervention: Religiously integrated cognitive behavioral therapy (RCBT)
Number of subjects: 132
Study 26219426 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive behavioral therapy (SCBT)
Number of subjects: 132
Study 26219426 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline religiosity
Number of subjects: 132
Study 26219426 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline optimism
Number of subjects: 132
Study 23336668 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride/metformin sustained release (GM-SR) 2/500 mg once daily
Number of subjects: 207
Study 23336668 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride/metformin (GM) 1/250 mg twice daily
Number of subjects: 207
Study 21330239 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent (BES) with biodegradable polymer
Number of subjects: 497
Study 21330239 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES) with durable polymer
Number of subjects: 497
Study 18926655 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic biliary drainage (PTBD)
Number of subjects: 419
Study 16894414 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary gland scintigraphy (SGS)
Number of subjects: 20
Study 16894414 — intervention group
Group type: COMPARATOR
Intervention: Salivary gland ultrasonography (SUS)
Number of subjects: 20
Study 15073257 — intervention group
Group type: EXPERIMENTAL
Intervention: (188)Re-HDD/lipiodol therapy
Number of subjects: 23
Study 15073257 — intervention group
Group type: COMPARATOR
Intervention: (131)I-lipiodol therapy
Number of subjects: 23
Study 11468763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative logit models for ordinal data analysis using longitudinal allergy data.
Number of subjects: 0
Study 11468763 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian approach to modeling.
Number of subjects: 0
Study 9565408 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored written feedback based on chart reviews and relevant articles sent to intervention group (n=72) during a 3-month period.
Number of subjects: 147
Study 9565408 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=75) received no tailored feedback.
Number of subjects: 147
Study 29996359 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based sealant (Group R)
Number of subjects: 419
Study 29996359 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer sealant (Group G)
Number of subjects: 419
Study 29996359 — intervention group
Group type: COMPARATOR
Intervention: None (Control Group N)
Number of subjects: 419
Study 28704625 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulation (SM)
Number of subjects: 24
Study 28704625 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 24
Study 26524571 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture sessions (12 sessions, 600 minutes total) plus usual care
Number of subjects: 517
Study 26524571 — intervention group
Group type: EXPERIMENTAL
Intervention: Alexander Technique lessons (20 lessons, 600 minutes total) plus usual care
Number of subjects: 517
Study 26524571 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 517
Study 26524571 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Acupuncture and Alexander lessons)
Number of subjects: 517
Study 23331486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices providing comprehensive health assessments and referrals to care facilities.
Number of subjects: 24
Study 23331486 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by control practices.
Number of subjects: 24
Study 19781238 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Nirschl procedure
Number of subjects: 26
Study 19781238 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic Nirschl procedure
Number of subjects: 26
Study 19781238 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 26
Study 17347294 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic cleaning for 15 minutes
Number of subjects: 32
Study 17347294 — intervention group
Group type: COMPARATOR
Intervention: No decontamination (control)
Number of subjects: 32
Study 15078725 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (10 micro g/kg/min for 8 h every 14 days) + oral amiodarone (400 mg/d)
Number of subjects: 30
Study 15078725 — intervention group
Group type: COMPARATOR
Intervention: Placebo + oral amiodarone (400 mg/d)
Number of subjects: 30
Study 15078725 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Dobutamine and Placebo)
Number of subjects: 30
Study 11427359 — intervention group
Group type: EXPERIMENTAL
Intervention: Film-coated placebo risedronate tablet (oval)
Number of subjects: 28
Study 11427359 — intervention group
Group type: COMPARATOR
Intervention: Uncoated placebo tablet (round)
Number of subjects: 28
Study 9673606 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive preconception risk assessment and referral to primary care services
Number of subjects: 170
Study 9673606 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (no feedback provided)
Number of subjects: 170
Study 8018438 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational (PE) program
Number of subjects: 152
Study 8018438 — intervention group
Group type: COMPARATOR
Intervention: Standard information (INFO) condition
Number of subjects: 152
Study 2700320 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg twice daily for 15 days, then 40 mg twice daily for 45 days
Number of subjects: 60
Study 2700320 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg once daily for 60 days
Number of subjects: 60
Study 765382 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (100 mug 4 times daily)
Number of subjects: 42
Study 765382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 765382 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 42
Study 31038038 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative interventions for symptoms of postnatal depression
Number of subjects: 91
Study 27721190 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation for depression via telemedicine
Number of subjects: 241
Study 27721190 — intervention group
Group type: COMPARATOR
Intervention: Behavioral activation for depression via same-room treatment
Number of subjects: 241
Study 26125257 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine (group A)
Number of subjects: 91
Study 26125257 — intervention group
Group type: COMPARATOR
Intervention: Infrared polarized light therapy (group B)
Number of subjects: 91
Study 26125257 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin treatment (group C)
Number of subjects: 91
Study 26125257 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint treatment (group D)
Number of subjects: 91
Study 23164310 — intervention group
Group type: COMPARATOR
Intervention: Watching a DVD for 30 minutes
Number of subjects: 49
Study 23164310 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing with blocks for 30 minutes
Number of subjects: 49